Immortalized Cell Line Market Research Report - Global Forecast till 2027

Immortalized Cell Line Market Research Report: Information by Method (Virus Induction, HTERT Expression, Inactivation of Tumor Suppression Genes and others), Application (Diagnostics, Drug Discovery, Vaccine Production, Tissue Engineering and Regenerative Medicines and others), End User (Pharmaceutical and Biopharmaceutical Companies, Contract Research Organizations and Research Laboratories) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2027

ID: MRFR/LS/0267-CR | August, 2019 | Region : Global

1 Report Prologue

2 Executive Summary

3 Market Introduction

3.1 Scope of Study 19

3.2 Research Objective 19

3.3 List of Assumptions 19

3.4 Market Structure 20

4 Research Methodology

4.1 Research Process 22

4.2 Primary Research 23

4.3 Secondary Research 24

4.4 Market Size Estimation 25

4.5 Forecast Model 25

5 Market Dynamics

5.1 Introduction 27

5.2 Drivers 28

5.2.1 Increasing Application in Biotech & Pharmaceutical Companies and Hospitals 28

5.2.2 Growing Number of Patients in Need of Organ Transplantation 28

5.2.3 Rise in the Patient Population Affected by Cancer 29

5.3 Restraints 29

5.3.1 High Cost of Equipment 29

5.3.2 Developing Stable and Authentic Cell Lines 29

5.4 Opportunities 30

5.4.1 Entering Untapped Markets 30

5.4.2 Increasing Use of cell Line Culture in Cancer and Stem Cell Research 30

6 Market Factor Analysis

6.1 Porters Five Forces Analysis 32

6.1.1 Bargaining Power of Suppliers 32

6.1.2 Bargaining Power of Buyers 32

6.1.3 Threat of New Entrants 32

6.1.4 Threat of Substitutes 33

6.1.5 Intensity of Rivalry 33

6.2 Supply Chain Analysis 33

6.2.1 R&D 33

6.2.2 Manufacturing 33

6.2.3 Distribution & Sales 34

6.2.4 Post-Sales Monitoring 34

6.3 Investment Opportunities 34

6.4 Pricing Analysis 34

7 Immortalized Cell Line Market, by Method

7.1 Overview 36

7.1.1 Virus Induction 38

7.1.2 HTERT Expression 39

7.1.3 Inactivation of Tumour Suppression Genes 40

7.1.4 Others 40

8 Immortalized Cell Line Market, by Application

8.1 Overview 42

8.1.1 Diagnostics 43

8.1.2 Drug Discovery 43

8.1.3 Vaccine Production 44

8.1.4 Tissue Engineering and Regenerative Medicines 45

8.1.5 Others 45

9 Immortalized Cell Line Market, by End-user

9.1 Overview 47

9.1.1 Introduction 47

9.1.2 Pharmaceutical and Biopharmaceutical Companies 48

9.1.3 Contract Research Organizations 48

9.1.4 Research Laboratories 49

10 Global Immortalized Cell Line Market, By Region

10.1 Overview 51

10.2 Americas 52

Immortalized Cell Line Market, by Method

Immortalized Cell Line Market, by Application

Immortalized Cell Line Market, by End-user

10.2.1 North America 54

Immortalized Cell Line Market, by Method

Immortalized Cell Line Market, by Application

Immortalized Cell Line Market, by End-user

10.2.1.1 US 57

Immortalized Cell Line Market, by Method

Immortalized Cell Line Market, by Application

Immortalized Cell Line Market, by End-user

10.2.1.2 Canada 58

Immortalized Cell Line Market, by Method

Immortalized Cell Line Market, by Application

Immortalized Cell Line Market, by End-user

10.2.2 South America 60

Immortalized Cell Line Market, by Method

Immortalized Cell Line Market, by Application

Immortalized Cell Line Market, by End-user

10.3 Europe 62

Immortalized Cell Line Market, by Method

Immortalized Cell Line Market, by Application

Immortalized Cell Line Market, by End-user

10.3.1 Western Europe 65

Immortalized Cell Line Market, by Method

Immortalized Cell Line Market, by Application

Immortalized Cell Line Market, by End-user

10.3.1.1 Germany 67

Immortalized Cell Line Market, by Method

Immortalized Cell Line Market, by Application

Immortalized Cell Line Market, by End-user

10.3.1.2 France 69

Immortalized Cell Line Market, by Method

Immortalized Cell Line Market, by Application

Immortalized Cell Line Market, by End-user

10.3.1.3 UK 71

Immortalized Cell Line Market, by Method

Immortalized Cell Line Market, by Application

Immortalized Cell Line Market, by End-user

10.3.1.4 Italy 73

Immortalized Cell Line Market, by Method

Immortalized Cell Line Market, by Application

Immortalized Cell Line Market, by End-user

10.3.1.5 Spain 75

Immortalized Cell Line Market, by Method

Immortalized Cell Line Market, by Application

Immortalized Cell Line Market, by End-user

10.3.1.6 Rest of Western Europe 76

Immortalized Cell Line Market, by Method

Immortalized Cell Line Market, by Application

Immortalized Cell Line Market, by End-user

10.3.2 Eastern Europe 78

Immortalized Cell Line Market, by Method

Immortalized Cell Line Market, by Application

Immortalized Cell Line Market, by End-user

10.4 Asia-Pacific 80

Immortalized Cell Line Market, by Method

Immortalized Cell Line Market, by Application

Immortalized Cell Line Market, by End-user

10.4.1 Japan 82

Immortalized Cell Line Market, by Method

Immortalized Cell Line Market, by Application

Immortalized Cell Line Market, by End-user

10.4.2 China 84

Immortalized Cell Line Market, by Method

Immortalized Cell Line Market, by Application

Immortalized Cell Line Market, by End-user

10.4.3 India 86

Immortalized Cell Line Market, by Method

Immortalized Cell Line Market, by Application

Immortalized Cell Line Market, by End-user

10.4.4 South Korea 87

Immortalized Cell Line Market, by Method

Immortalized Cell Line Market, by Application

Immortalized Cell Line Market, by End-user

10.4.5 Rest of Asia-Pacific 89

Immortalized Cell Line Market, by Method

Immortalized Cell Line Market, by Application

Immortalized Cell Line Market, by End-user

10.5 Middle East and Africa 91

Immortalized Cell Line Market, by Method

Immortalized Cell Line Market, by Application

Immortalized Cell Line Market, by End-user

10.5.1 Middle East 93

Immortalized Cell Line Market, by Method

Immortalized Cell Line Market, by Application

Immortalized Cell Line Market, by End-user

10.5.2 Africa 95

Immortalized Cell Line Market, by Method

Immortalized Cell Line Market, by Application

Immortalized Cell Line Market, by End-user

11 Competitive Landscape

11.1 Company Market Share Analysis 98

11.1.1 Introduction 98

11.2 Competitive Landscape 99

11.2.1 Introduction 99

11.3 Key Developments 100

12 Company Profiles

12.1 Thermo Fisher Scientific 102

12.1.1 Company Overview 102

12.1.2 Financial Overview 102

12.1.3 Products Offered 103

12.1.4 Key Developments 103

12.1.5 SWOT Analysis 103

12.1.6 Key Strategies 104

12.2 ATCC (American Type Culture Collection Inc.) 105

12.2.1 Company Overview 105

12.2.2 Financial Overview 105

12.2.3 Products Offered 105

12.2.4 Key Developments 106

12.2.5 SWOT Analysis 107

12.2.6 Key Strategies 107

12.3 Valneva 108

12.3.1 Company Overview 108

12.3.2 Financial Overview 108

12.3.3 Products Offered 108

12.3.4 1.3.4 Key Developments 109

12.3.5 SWOT Analysis 109

12.3.6 Key Strategies 109

12.4 Sartorius AG 110

12.4.1 Company Overview 110

12.4.2 Financial Overview 110

12.4.3 Products Offered 111

12.4.4 Key Developments 111

12.4.5 SWOT Analysis 111

12.4.6 Key Strategies 111

12.5 Lonza Group, AG 112

12.5.1 Company Overview 112

12.5.2 Financial Overview 112

12.5.3 Products Offered 112

12.5.4 Key Developments 113

12.5.5 Swot Analysis 113

12.5.6 Key Strategies 113

12.6 Merck KGaA 114

12.6.1 Company Overview 114

12.6.2 Financial Overview 114

12.6.3 Products Offered 115

12.6.4 Key Developments 115

12.6.5 SWOT Analysis 115

12.6.6 Key Strategies 115

12.7 Selexis SA 116

12.7.1 Company Overview 116

12.7.2 Financial Overview 116

12.7.3 Products Offered 116

12.7.4 Key Developments 116

12.7.5 SWOT Analysis 117

12.7.6 Key Strategies 117

12.8 Wuxi App Tec 118

12.8.1 Company Overview 118

12.8.2 Financial Overview 118

12.8.3 Products Offered 119

12.8.4 Key Developments 119

12.8.5 SWOT Analysis 119

12.8.6 Key Strategies 119

12.9 European Collection of Authenticated Cell Cultures (ECACC) 120

12.9.1 Company Overview 120

12.9.2 Financial Overview 120

12.9.3 Products Offered 120

12.9.4 Key Developments 120

12.9.5 SWOT Analysis 121

12.9.6 Key Strategies 121

12.10 Corning Incorporated 122

12.10.1 Company Overview 122

12.10.2 Financial Overview 122

12.10.3 Products Offered 123

12.10.4 Key Developments 123

12.10.5 SWOT Analysis 123

12.10.6 Key Strategies 123

13 Appendix

13.1 Discussion Blue Print 125

14 List of Tables

TABLE 1 MARKET SYNOPSIS 17

TABLE 2 LIST OF ASSUMPTIONS 19

TABLE 3 GLOBAL IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 36

TABLE 4 GLOBAL IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 37

TABLE 5 GLOBAL IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 37

TABLE 6 GLOBAL IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY REGION 2020–2027 (USD MILLION) 38

TABLE 7 GLOBAL IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY REGION 2020–2027 (USD MILLION) 39

TABLE 8 GLOBAL IMMORTALIZED CELL LINE MARKET FOR INACTIVATION OF TUMOUR SUPPRESSION GENES, BY REGION 2020–2027 (USD MILLION) 40

TABLE 9 GLOBAL IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 42

TABLE 10 GLOBAL IMMORTALIZED CELL LINE MARKET FOR DIAGNOSTICS, BY REGION 2020–2027 (USD MILLION) 43

TABLE 11 GLOBAL IMMORTALIZED CELL LINE MARKET FOR DRUG DISCOVERY, BY REGION 2020–2027 (USD MILLION) 43

TABLE 12 GLOBAL IMMORTALIZED CELL LINE MARKET FOR VACCINE PRODUCTION, BY REGION 2020–2027 (USD MILLION) 44

TABLE 13 GLOBAL IMMORTALIZED CELL LINE MARKET FOR TISSUE ENGINEERING & REGENERATIVE MEDICINE, BY REGION 2020–2027 (USD MILLION) 45

TABLE 14 GLOBAL IMMORTALIZED CELL LINE MARKET, BY END-USERS 2020–2027 (USD MILLION) 47

TABLE 15 GLOBAL IMMORTALIZED CELL LINE MARKET FOR PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, BY REGION 2020–2027 (USD MILLION) 48

TABLE 16 GLOBAL IMMORTALIZED CELL LINE MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION 2020–2027 (USD MILLION) 48

TABLE 17 GLOBAL IMMORTALIZED CELL LINE MARKET FOR RESEARCH LABORATORIES, BY REGION 2020–2027 (USD MILLION) 49

TABLE 18 GLOBAL IMMORTALIZED CELL LINE MARKET, BY REGION 2020–2027 (USD MILLION) 51

TABLE 19 GLOBAL IMMORTALIZED CELL LINE MARKET, BY REGION 2020 & 2027 (USD MILLION) 51

TABLE 20 AMERICAS IMMORTALIZED CELL LINE MARKET, BY REGION 2020–2027 (USD MILLION) 52

TABLE 21 AMERICAS IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 53

TABLE 22 AMERICAS IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 53

TABLE 23 AMERICAS IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 53

TABLE 24 AMERICAS IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 54

TABLE 25 AMERICAS IMMORTALIZED CELL LINE MARKET, BY END-USERS 2020–2027 (USD MILLION) 54

TABLE 26 NORTH AMERICAS IMMORTALIZED CELL LINE MARKET, BY COUNTRY 2020–2027 (USD MILLION) 54

TABLE 27 NORTH AMERICAS IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 55

TABLE 28 NORTH AMERICAS IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 55

TABLE 29 NORTH AMERICAS IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 56

TABLE 30 NORTH AMERICAS IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 56

TABLE 31 NORTH AMERICAS IMMORTALIZED CELL LINE MARKET, BY END-USER 2020–2027 (USD MILLION) 56

TABLE 32 US IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 57

TABLE 33 US IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 57

TABLE 34 US IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 57

TABLE 35 US IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 58

TABLE 36 US IMMORTALIZED CELL LINE MARKET, BY END-USER 2020–2027 (USD MILLION) 58

TABLE 37 CANADA IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USDMILLION) 58

TABLE 38 CANADA IMMORTALIZED CELL LINE MARKET FOR VIRCANADA INDUCTION, BY TYPE 2020–2027 (USDMILLION) 59

TABLE 39 CANADA IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USDMILLION) 59

TABLE 40 CANADA IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USDMILLION) 59

TABLE 41 CANADA IMMORTALIZED CELL LINE MARKET, BY END-USER 2020–2027 (USDMILLION) 60

TABLE 42 SOUTH AMERICA IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 60

TABLE 43 SOUTH AMERICA IMMORTALIZED CELL LINE MARKET FOR VIRSOUTH AMERICA INDUCTION, BY TYPE 2020–2027 (USD MILLION) 60

TABLE 44 SOUTH AMERICA IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 61

TABLE 45 SOUTH AMERICA IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 61

TABLE 46 SOUTH AMERICA IMMORTALIZED CELL LINE MARKET, BY END-USER 2020–2027 (USD MILLION) 61

TABLE 47 EUROPE IMMORTALIZED CELL LINE MARKET, BY REGION 2020–2027 (USD MILLION) 62

TABLE 48 EUROPE IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 63

TABLE 49 EUROPE IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 63

TABLE 50 EUROPE IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 63

TABLE 51 EUROPE IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 64

TABLE 52 EUROPE IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 64

TABLE 53 WESTERN EUROPE: IMMORTALIZED CELL LINE MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 65

TABLE 54 WESTERN EUROPE IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 65

TABLE 55 WESTERN EUROPE IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 66

TABLE 56 WESTERN EUROPE IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 66

TABLE 57 WESTERN EUROPE IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 66

TABLE 58 WESTERN EUROPE IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 67

TABLE 59 GERMANY IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 67

TABLE 60 GERMANY IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 67

TABLE 61 GERMANY IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 68

TABLE 62 GERMANY IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 68

TABLE 63 GERMANY IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 68

TABLE 64 FRANCE IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 69

TABLE 65 FRANCE IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 69

TABLE 66 FRANCE IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 69

TABLE 67 FRANCE IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 70

TABLE 68 FRANCE IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 70

TABLE 69 U.K IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 71

TABLE 70 U.K IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 71

TABLE 71 U.K IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 71

TABLE 72 U.K IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 72

TABLE 73 U.K IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 72

TABLE 74 ITALY IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 73

TABLE 75 ITALY IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 73

TABLE 76 ITALY IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 73

TABLE 77 ITALY IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 74

TABLE 78 ITALY IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 74

TABLE 79 SPAIN IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 75

TABLE 80 SPAIN IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 75

TABLE 81 SPAIN IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 75

TABLE 82 SPAIN IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 76

TABLE 83 SPAIN IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 76

TABLE 84 REST OF WESTERN EUROPE IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 76

TABLE 85 REST OF WESTERN EUROPE IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 77

TABLE 86 REST OF WESTERN EUROPE IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 77

TABLE 87 REST OF WESTERN EUROPE IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 77

TABLE 88 REST OF WESTERN EUROPE IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 78

TABLE 89 EASTERN EUROPE IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 78

TABLE 90 EASTERN EUROPE IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 78

TABLE 91 EASTERN EUROPE IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 79

TABLE 92 EASTERN EUROPE IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 79

TABLE 93 EASTERN EUROPE IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 79

TABLE 94 ASIA PACIFIC: IMMORTALIZED CELL LINE MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 80

TABLE 95 ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 81

TABLE 96 ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 81

TABLE 97 ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 81

TABLE 98 ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 82

TABLE 99 ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 82

TABLE 100 JAPAN IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 82

TABLE 101 JAPAN IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 83

TABLE 102 JAPAN IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 83

TABLE 103 JAPAN IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 83

TABLE 104 JAPAN IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 84

TABLE 105 CHINA IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 84

TABLE 106 CHINA IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 84

TABLE 107 CHINA IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 85

TABLE 108 CHINA IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 85

TABLE 109 CHINA IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 85

TABLE 110 INDIA IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 86

TABLE 111 INDIA IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 86

TABLE 112 INDIA IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 86

TABLE 113 INDIA IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 87

TABLE 114 INDIA IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 87

TABLE 115 SOUTH KOREA IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 87

TABLE 116 SOUTH KOREA IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 88

TABLE 117 SOUTH KOREA IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 88

TABLE 118 SOUTH KOREA IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 88

TABLE 119 SOUTH KOREA IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 89

TABLE 120 REST OF ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 89

TABLE 121 REST OF ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 89

TABLE 122 REST OF ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 90

TABLE 123 REST OF ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 90

TABLE 124 REST OF ASIA-PACIFIC IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 90

TABLE 125 MIDDLE EAST AND AFRICA: IMMORTALIZED CELL LINE MARKET, BY REGION, 2020–2027 (USD MILLION) 91

TABLE 126 MIDDLE EAST AND AFRICA IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 92

TABLE 127 MIDDLE EAST AND AFRICA IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 92

TABLE 128 MIDDLE EAST AND AFRICA IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 92

TABLE 129 MIDDLE EAST AND AFRICA IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 93

TABLE 130 MIDDLE EAST AND AFRICA IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 93

TABLE 131 MIDDLE EAST IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 93

TABLE 132 MIDDLE EAST IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 94

TABLE 133 MIDDLE EAST IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 94

TABLE 134 MIDDLE EAST IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 94

TABLE 135 MIDDLE EAST IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 95

TABLE 136 AFRICA IMMORTALIZED CELL LINE MARKET, BY METHOD 2020–2027 (USD MILLION) 95

TABLE 137 AFRICA IMMORTALIZED CELL LINE MARKET FOR VIRUS INDUCTION, BY TYPE 2020–2027 (USD MILLION) 95

TABLE 138 AFRICA IMMORTALIZED CELL LINE MARKET FOR HTERT EXPRESSION, BY TYPE 2020–2027 (USD MILLION) 96

TABLE 139 AFRICA IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020–2027 (USD MILLION) 96

TABLE 140 AFRICA IMMORTALIZED CELL LINE MARKET, BY END USERS 2020–2027 (USD MILLION) 96

TABLE 141 GLOBAL IMMORTALIZED CELL LINE MARKET: KEY DEVELOPMENTS 100

15 List of Figures

FIGURE 1 GLOBAL IMMORTALIZED CELL LINE MARKET: MARKET STRUCTURE 20

FIGURE 2 RESEARCH PROCESS OF MRFR 22

FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH 25

FIGURE 4 PORTERS FIVE FORCES ANALYSIS OF GLOBAL IMMORTALIZED CELL LINE MARKET 32

FIGURE 5 SUPPLY CHAIN: GLOBAL IMMORTALIZED CELL LINE MARKET 33

FIGURE 6 GLOBAL IMMORTALIZED CELL LINE MARKET, BY METHOD 2020 & 2027 (USD MILLION) 36

FIGURE 7 GLOBAL IMMORTALIZED CELL LINE MARKET, BY APPLICATION 2020 & 2027 (USD MILLION) 42

FIGURE 8 GLOBAL IMMORTALIZED CELL LINE MARKET, BY END-USERS 2020 & 2027 (USD MILLION) 47

FIGURE 9 AMERICAS IMMORTALIZED CELL LINE MARKET, BY REGION 2020 (%) 52

FIGURE 10 NORTH AMERICAS IMMORTALIZED CELL LINE MARKET, BY REGION 2020 (%) 55

FIGURE 11 EUROPE: IMMORTALIZED CELL LINE MARKET SHARE, BY REGION, 2020 (% SHARE) 62

FIGURE 12 WESTERN EUROPE: IMMORTALIZED CELL LINE MARKET, BY COUNTRY, 2020 (%) 65

FIGURE 13 ASIA PACIFIC: IMMORTALIZED CELL LINE MARKET SHARE, BY COUNTRY, 2020 (%) 80

FIGURE 14 THE MIDDLE EAST AND AFRICA: IMMORTALIZED CELL LINE MARKET SHARE, BY REGION, 2020 (%) 91

FIGURE 15 GLOBAL IMMORTALIZED CELL LINE MARKET, MARKET SHARE ANALYSIS 2020 (%) 98

FIGURE 16 GLOBAL IMMORTALIZED CELL LINE MARKET COMPETITIVE LANDSCAPE (%) 99

Immortalized Cell Line Market Speak to Analyst Request a Free Sample

Global Immortalized Cell Line Market: Competitive Landscape


Lonza Group AG, Corning Incorporated, Thermo Fisher Scientific, and Selexis SA collectively accounted for more than 65.1% of the market share of the global immortalized cell line market in 2017. These companies continue to retain their strong global presence through expansions, mergers & acquisitions, and agreements.


In 2017, Lonza Group AG was the leading player in the market. The company pursued a strategy of acquisitions and expansions to strengthen its position in the global market. The company leverages its expertise in pharmaceuticals and biotech and specialty ingredients to develop new products. The company has a strong foothold with more than 100 sites and offices and approximately 14,500 full-time employees worldwide. Its dominance is likely to remain unchallenged during the assessment period.


Corning Incorporated held the second position in terms of market share, in 2017. It focuses on its strategic decision to work on flexible business models to enable customized solutions to satisfy the unique needs of clients. The company is the innovator in medical science, with expertise in glass science, ceramic science, and optical physics. The company has its research centers in North America, Europe, and Asia. The firm has its products manufactured in over 17 countries. Moreover, it also works in the segment that provides innovative solutions, improving improve productivity and enabling breakthrough discoveries in life science division.


Thermo Fisher Scientific acquired the third spot in the market. The company is focused on technically magnificent products and skilled workforce, which assists its customers to accelerate life science research as well as getting better outcomes in challenging clinical research fields. It also focusses on the pricing of products to provide attractive volume expansion opportunities. The company has adopted the strategy of acquisitions to increase its share in the market. For this, the company acquired Patheon for USD 7.2 million. Patheon’s CDMO services are likely to complement Thermo Fisher Scientific’s life sciences technologies designed to support research, clinical trials, and production.


Selexis SA is one of the most competitive players in this market. The company is engaged in providing mammalian cell-line generation technologies to facilitate the development and translation of new therapies into life-saving medicines. Additionally, the company provides cell-line development, lead identification, and genomic characterization services. The company focuses on providing breakthrough technologies fundamentally impacting and improving drug discovery, drug development, and biopharmaceutical manufacturing.


In the near future, the strategies to gain a significant market share in this growing industry have been varying from acquisitions and agreements to expansions. The established companies are busy in acquiring companies and entering into the agreement with other ecosystem players. Acquisitions are a key focus area for players as the demand for cost-effective and efficient immortal cell lines for numerous applications such as drug discovery, vaccine production, diagnosis, and tissue regeneration, among others is growing rapidly. This surges the growth of the global immortalized cell line market.